CatSci Opens New Dagenham Laboratory

CatSci Ltd. has opened a new analytical science laboratory in Dagenham, UK. The new facility is equipped with state-of-the-art analytical equipment through a collaboration with Shimadzu Corporation. A key early milestone in CatSci’s $3.5 million investment plan, this new dedicated analytical resource further positions CatSci as an innovation partner in medicines development that can add strategic value to customers, addressing their evolving CMC challenges and de-risking their pharmaceutical pipelines.

The demand for solving multi-disciplinary analytical problems is growing with the advent of new modalities and asset classes, such as oligonucleotides and cannabinoids. At the same time, new or modified regulatory requirements such as nitrosamine determinations and trace impurity analysis require the development of highly specific and sensitive methods.

“The opening of our analytical laboratory at LondonEast in Dagenham, UK is an exciting step on our journey towards becoming a fully integrated CMC company that accelerates medicine development to deliver best-in-class therapeutics to those in need,” said Ross Burn, CEO, CatSci. “Solving complex challenges that our customers face is at the core of what we do and this new facility, filled with Shimadzu’s cutting-edge equipment, sets a new exemplary standard for measurement science in the industry.”

Nigel Richardson, director of analytical technology and new modalities, said, “We’re excited to leverage our large pharma heritage across the CMC landscape and excellence in analytical science to work seamlessly with our customers to solve their analytical chemistry challenges with speed and scientific integrity. The opening of this new facility deepens the level of support we can offer. We will also be upgrading the site with capacity for GMP analytical development and testing, which will further increase our ability to provide innovative, tailored solutions from early development pre-clinical data packages to late development Phase III impurity fate studies.”